Fluorescence optical imaging in pediatric patients with inflammatory and non-inflammatory joint diseases: a comparative study with ultrasonography

Beck, Marisa Christin; Glimm, Anne-Marie; Ohrndorf, Sarah; Minden, Kirsten; Trauzeddel, Ralf; Werner, Stephanie Gabriele; Horneff, Gerd; Backhaus, Marina; Burmester, Gerd Rüdiger; Kallinich, Tilmann; Girschick, Hermann; Klotsche, Jens

doi:10.1186/s13075-017-1440-8

Table 1 Demographic and clinical data of the study population

From: Fluorescence optical imaging in pediatric patients with inflammatory and non-inflammatory joint diseases: a comparative study with ultrasonography

	Group I: JIA patients with clinically active arthritis in the hand region		Group II: non-inflammatory joint diseases		Group III: all JIA patients
	(n = 29)		(n = 23)		(n = 53)
	n	%	n	%	n	%
Gender
Female	23	79	19	83	45	85
Male	6	21	4	17	8	15
Age (years), mean (SD); median	13.7 (3.3); 14.0		13.8 (2.4); 14.9		13.7 (3.3); 14.1
Disease duration (years), mean (SD); median	3.3 (4.0); 1.6		1.7 (1.8); 1.1		3.7 (4.1); 2.1
Diagnosis
Juvenile idiopathic arthritis	29	100.0	n.a.	n.a.	53	100.0
Systemic arthritis	0	0.0	n.a.	n.a.	1	2
Oligoarthritis, persistent	0	0.0	n.a.	n.a.	6	11
Oligoarthritis, extended	0	0.0	n.a.	n.a.	1	2
Polyarthritis, seronegative	19	66	n.a.	n.a.	28	53
Polyarthritis, seropositive	5	17	n.a.	n.a.	7	13
Enthesitis-related arthritis	2	7	n.a.	n.a.	6	11
Psoriatic arthritis	2	7	n.a.	n.a.	3	6
Other arthritis	1	3	n.a.	n.a.	1	2
Arthralgia	n.a.	n.a.	23	100	n.a.	n.a.
Physician’s global assessment (NRS 0–10)
Mean (SD)	3.4 (1.9)		n.a.		2.4 (1.9)
Inactive disease (NRS < 1)	0	0.0	n.a	n.a.	9	17
Therapy
Nonsteroidal anti-inflammatory drugs	20	69	10	43.5	31	59
Systemic glucocorticoids, low dose	5	17	0	0.0	6	11
Systemic glucocorticoids, high dose	3	10	0	0.0	3	6
Disease-modifying antirheumatic drugs	19	65	0	0.0	32	60
Methotrexate	15	52	0	0.0	23	43
Sulfasalazine	2	7	0	0.0	3	6
Leflunomide	1	3	0	0.0	1	2
Etanercept	4	14	0	0.0	6	11
Adalimumab	0	0.0	0	0.0	3	6
Abatacept	1	3	0	0.0	1	2
Tocilizumab	2	7	0	0.0	2	4
Canakinumab	1	3	0	0.0	1	2
ESR (mm/h), mean (SD); n	17.0 (19.2); 24		9.5 (6.5); 21		14.8 (16.1); 44
CRP (mg/dl), mean (SD); n	0.4 (0.5); 28		0.1 (0.1); 23		0.3 (0.5); 48
cJADAS-10
Mean (SD)	13.3 (4.8)		n.a		9.5 (5.9)
Inactive disease (cJADAS-10 ≤ 1)	0	0.0	n.a.		3	6
CHAQ
Mean (SD)	0.7 (0.6)		0.5 (0.6)		0.5 (0.6)
No functional disability (CHAQ = 0)	7	24	8	27	16	30
Patient’s Global Assessment (NRS 0–10), mean (SD)	2.6 (2.2)		3.9 (3.4)		2.6 (2.2)

JIA juvenile idiopathic arthritis, SD standard deviation, n.a. not applicable, NRS numerical rating scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, cJADAS clinical Juvenile Arthritis Disease Activity Score, CHAQ Childhood Health Assessment Questionnaire

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us